{"name":"Pierre Fabre Medicament","slug":"pierre-fabre-medicament","ticker":"","exchange":"","domain":"pierrefabremedicament.com","description":"","hq":"Lavaur","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"DC071","genericName":"DC071","slug":"dc071","indication":"Other","status":"marketed"},{"name":"Strefen","genericName":"Strefen","slug":"strefen","indication":"Other","status":"phase_2"},{"name":"Tamsulosine Arrow LP","genericName":"Tamsulosine Arrow LP","slug":"tamsulosine-arrow-lp","indication":"Benign prostatic hyperplasia with lower urinary tract symptoms","status":"marketed"},{"name":"Tamsulosine LP","genericName":"Tamsulosine LP","slug":"tamsulosine-lp","indication":"Other","status":"marketed"},{"name":"Bronchodilatator","genericName":"Bronchodilatator","slug":"bronchodilatator","indication":"Other","status":"phase_1"},{"name":"J022X ST","genericName":"J022X ST","slug":"j022x-st","indication":"Other","status":"phase_3"},{"name":"Phytotherapy","genericName":"Phytotherapy","slug":"phytotherapy","indication":"Other","status":"phase_2"},{"name":"Placebo matching Tamsulosine Arrow LP","genericName":"Placebo matching Tamsulosine Arrow LP","slug":"placebo-matching-tamsulosine-arrow-lp","indication":"Clinical trial control for benign prostatic hyperplasia studies","status":"marketed"},{"name":"Placebo matching Tamsulosine LP","genericName":"Placebo matching Tamsulosine LP","slug":"placebo-matching-tamsulosine-lp","indication":"Placebo control for clinical trials of Tamsulosin LP in benign prostatic hyperplasia","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"cardiovascular","drugs":[{"name":"Binimetinib Oral Tablet","genericName":"Binimetinib Oral Tablet","slug":"binimetinib-oral-tablet","indication":"Melanoma","status":"phase_2"},{"name":"Encorafenib and Binimetinib","genericName":"Encorafenib and Binimetinib","slug":"encorafenib-and-binimetinib","indication":"Unresectable or metastatic melanoma with BRAF V600E or V600K mutation","status":"phase_3"},{"name":"F2695","genericName":"F2695","slug":"f2695","indication":"Advanced or metastatic solid tumors with FGFR alterations","status":"phase_3"},{"name":"V0034CR01B","genericName":"V0034CR01B","slug":"v0034cr01b","indication":"Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)","status":"phase_3"},{"name":"Vinflunine plus Capecitabine","genericName":"Vinflunine plus Capecitabine","slug":"vinflunine-plus-capecitabine","indication":"Advanced or metastatic transitional cell carcinoma of the urothelial tract","status":"phase_3"},{"name":"vinflunine and best supportive care","genericName":"vinflunine and best supportive care","slug":"vinflunine-and-best-supportive-care","indication":"Advanced or metastatic transitional cell carcinoma of the urothelial tract","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"desonide 0.1% cream","genericName":"desonide 0.1% cream","slug":"desonide-0-1-cream","indication":"Eczema","status":"phase_3"},{"name":"Locatop@","genericName":"Locatop@","slug":"locatop","indication":"Inflammatory skin conditions (eczema, dermatitis, psoriasis)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"F17464","genericName":"F17464","slug":"f17464","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Locapred@","genericName":"Locapred@","slug":"locapred","indication":"Inflammatory skin conditions (specific indication in Phase 3 development unclear from available data)","status":"phase_3"}]}],"pipeline":[{"name":"DC071","genericName":"DC071","slug":"dc071","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Strefen","genericName":"Strefen","slug":"strefen","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tamsulosine Arrow LP","genericName":"Tamsulosine Arrow LP","slug":"tamsulosine-arrow-lp","phase":"marketed","mechanism":"Tamsulosin is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow.","indications":["Benign prostatic hyperplasia with lower urinary tract symptoms"],"catalyst":""},{"name":"Tamsulosine LP","genericName":"Tamsulosine LP","slug":"tamsulosine-lp","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"desonide 0.1% cream","genericName":"desonide 0.1% cream","slug":"desonide-0-1-cream","phase":"phase_3","mechanism":"Desonide is a topical corticosteroid that reduces inflammation by inhibiting the production of pro-inflammatory mediators.","indications":["Eczema","Psoriasis"],"catalyst":""},{"name":"Binimetinib Oral Tablet","genericName":"Binimetinib Oral Tablet","slug":"binimetinib-oral-tablet","phase":"phase_2","mechanism":"MEK1/2 inhibitor","indications":["Melanoma"],"catalyst":""},{"name":"Bronchodilatator","genericName":"Bronchodilatator","slug":"bronchodilatator","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Encorafenib and Binimetinib","genericName":"Encorafenib and Binimetinib","slug":"encorafenib-and-binimetinib","phase":"phase_3","mechanism":"Encorafenib and binimetinib are a combination of a BRAF inhibitor and a MEK inhibitor that block the MAPK signaling pathway in BRAF-mutant melanoma cells.","indications":["Unresectable or metastatic melanoma with BRAF V600E or V600K mutation","BRAF-mutant colorectal cancer (in combination, pipeline indication)"],"catalyst":""},{"name":"F17464","genericName":"F17464","slug":"f17464","phase":"phase_2","mechanism":"F17464 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"F2695","genericName":"F2695","slug":"f2695","phase":"phase_3","mechanism":"F2695 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cancer cells.","indications":["Advanced or metastatic solid tumors with FGFR alterations"],"catalyst":""},{"name":"J022X ST","genericName":"J022X ST","slug":"j022x-st","phase":"phase_3","mechanism":"J022X ST is a tyrosine kinase inhibitor that targets specific molecular pathways involved in cancer cell proliferation and survival.","indications":[],"catalyst":""},{"name":"Locapred@","genericName":"Locapred@","slug":"locapred","phase":"phase_3","mechanism":"Locapred is a topical corticosteroid that reduces inflammation and immune response in localized skin conditions.","indications":["Inflammatory skin conditions (specific indication in Phase 3 development unclear from available data)"],"catalyst":""},{"name":"Locatop@","genericName":"Locatop@","slug":"locatop","phase":"phase_3","mechanism":"Locatop is a topical corticosteroid that reduces inflammation and immune response in skin conditions by binding to glucocorticoid receptors.","indications":["Inflammatory skin conditions (eczema, dermatitis, psoriasis)","Localized inflammatory dermatological disorders"],"catalyst":""},{"name":"Phytotherapy","genericName":"Phytotherapy","slug":"phytotherapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo matching Tamsulosine Arrow LP","genericName":"Placebo matching Tamsulosine Arrow LP","slug":"placebo-matching-tamsulosine-arrow-lp","phase":"marketed","mechanism":"This is a placebo formulation designed to match the appearance and administration profile of Tamsulosin Arrow LP, a selective alpha-1A adrenergic receptor antagonist used in benign prostatic hyperplasia treatment.","indications":["Clinical trial control for benign prostatic hyperplasia studies"],"catalyst":""},{"name":"Placebo matching Tamsulosine LP","genericName":"Placebo matching Tamsulosine LP","slug":"placebo-matching-tamsulosine-lp","phase":"marketed","mechanism":"This is a placebo formulation designed to match the appearance and administration profile of Tamsulosin LP (long-acting tamsulosin) for use in clinical trials.","indications":["Placebo control for clinical trials of Tamsulosin LP in benign prostatic hyperplasia"],"catalyst":""},{"name":"V0034CR01B","genericName":"V0034CR01B","slug":"v0034cr01b","phase":"phase_3","mechanism":"This drug is a selective inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.","indications":["Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)","Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL)"],"catalyst":""},{"name":"Vinflunine plus Capecitabine","genericName":"Vinflunine plus Capecitabine","slug":"vinflunine-plus-capecitabine","phase":"phase_3","mechanism":"Vinflunine is a chemotherapeutic agent that intercalates DNA, thereby inhibiting DNA replication and transcription, while Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase.","indications":["Advanced or metastatic transitional cell carcinoma of the urothelial tract"],"catalyst":""},{"name":"vinflunine and best supportive care","genericName":"vinflunine and best supportive care","slug":"vinflunine-and-best-supportive-care","phase":"phase_3","mechanism":"Vinflunine is a chemotherapeutic agent that works by intercalating DNA and inhibiting the enzyme topoisomerase II, thereby inducing apoptosis in cancer cells.","indications":["Advanced or metastatic transitional cell carcinoma of the urothelial tract"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxQeXM5dzR5YVFhUXVmUkxCS0xlZzd5NDFYRXhtV0NqTUNONEhQN0ZpRXNhNjdxeE9uNzRkVnFQanM2cXJ6a1R5bWxPSFUwN204cm5CYmZ5UnduMV9Sd3pSQzlNazdKb0h2M0pvaEp5UGZmcjZ2dE84amZGNFZENWFUZ25fNVA3cFV3RHpmVXBCRXRPMl9QVDd3YXlNcWVhMllTbGtlN3BVWlV4SUtMWTllTWlfNnF6czkxcHdhc1JNb1JMU2FTTzhSc05FTXlpMjhZVEIwM0xwQnpZNlVrZzl4d0V2NkE2RFpTMjRCOHBXQS1qVlRVZkhMQnlaYzVQeEZMUXRVTnpXLUZ3RU1tUXR0bGhXN0VIYmQtZ3pOLWFsMlFWQ3czOEY1NFE4N3c2WU1lOEE?oc=5","date":"2026-03-12","type":"regulatory","source":"PR Newswire","summary":"Pierre Fabre Pharmaceuticals Announces Type A Meeting Agreed with U.S. Food and Drug Administration (FDA) for Tabelecleucel Biologic License Application (BLA) - PR Newswire","headline":"Pierre Fabre Pharmaceuticals Announces Type A Meeting Agreed with U.S. Food and Drug Administration (FDA) for Tabelecleu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOOVFxZWxKakNERTRJY2liTjBJd1FscmtUMlNDRkhwT2ctY3hDVFRPSEtPZjUtT3VlR0R5a202aW10dUhnU0xUMWZBeWg2bVVhMTZxTmYzbGhacWVTQkJyTmVhUkNNY0JYcnQ1LUhBeXVNRDFadUNReHBTU2QzNFo3STRSeTUzYkQyZFZuYkZQdzRqWlB4eWZiTDREcXpvazRSRWJsY1B1TjdYVTZLaS1ma3RJQ0pjNFk5X2llYjN0RTlvY3VDaG1XYVlxNGtiY2VX?oc=5","date":"2026-03-04","type":"regulatory","source":"Pharmaceutical Commerce","summary":"Eton Pharmaceuticals Expands Rare Disease Portfolio with Acquisition of US Hemangeol Rights - Pharmaceutical Commerce","headline":"Eton Pharmaceuticals Expands Rare Disease Portfolio with Acquisition of US Hemangeol Rights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxPVmhPaFNNVE45RFZJZzVwcW9oYmVKNWNmZTdMYVB3RDFWeUpYb1ZMZTE1X0NBMVpDRm5VNmdrRk44SzVKTklhS2pHS3pDbmxpYkZYelRMbzIwV2NGdk94ZnFqV0FsR19VY3NfMFU0WklXb2N1bXVaV3REUFdHZ3I2ajJoQUdnYWJQVkNoYXBUVkdHSktaQklKeDA2WVNuLUtFdS1ES2hLRHZMQUdjdlhsMzlva3JQNWF4TWxNWlFHYlloYW9kN2RxZE9HeHdPVjM1RmVDNHlBNFBEOEhWckE4QW82THY3Zi1fOVkxOFRmSF9qcU9HZ016UmtDOTZpV2NCLXhtSzZPYm1oZGRCSjBPbFh4a3UxaTF6cUhsVGNTUF94eVQ4dlBUOXJVUkJRQQ?oc=5","date":"2026-03-03","type":"regulatory","source":"PR Newswire","summary":"Pierre Fabre Pharmaceuticals Submits Type A Meeting Request to U.S. Food and Drug Administration (FDA) for Tabelecleucel Biologic License Application (BLA) - PR Newswire","headline":"Pierre Fabre Pharmaceuticals Submits Type A Meeting Request to U.S. Food and Drug Administration (FDA) for Tabelecleucel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAJBVV95cUxNVm1LbnE5TEtYejhQNjZDYWRZZXhiSkZJNTNJRGlZX1h0X1lWdm1ORTlCVEk1U3E5N0IydkF1bnFuUTBaQnczRkpSWjBVYnRGQjRfTmluQlFwWldKUi1kaGR6XzdHWENzZ0dKN2piVXM4T2dqRmEzXzlvYXlBajVkdkRTSXVfV2JfQUlLVVdKWDNiV1AxT1BLYjBIX2xBVXQzNmpxNTBVY1lUYWZQcndKQU5FNVNtYmxsbXEtbF9ISEZCRjRsRmNBbzY2d19nX05wYklsOTZOWUVSMzdaa1MxSTlmMS1fZzhKUUgxUjhQdU15Tk5oVnRYWTBsdzdiUllybTlmS3paSTE2QWdsN2xkNi1SUDhoZUF5Rl80U3RIa0JneXMwLWlfUmMzSk10UWRDclRibnllem14cHRHZWRBRGRrTHh1U3NxZXlvYQ?oc=5","date":"2026-03-02","type":"pipeline","source":"GlobeNewswire","summary":"Eton Pharmaceuticals Expands Rare Disease Portfolio Through - GlobeNewswire","headline":"Eton Pharmaceuticals Expands Rare Disease Portfolio Through","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxNVjNqUnRFNk51aWdrMUpSWHdaQUlaclNMb09JX1FSelUxb0R0b1JFX09OU29MMzh4cEFnTnljc2tINXBMWF9aWmpvUWI3T2lOeHRPLXZwRFBHdGxBdHE2Q3JjMzVmOS1raDJDbHNZeDJOU3pQS2RzMG9uOFBza2pnUTFaOFQ4c1FodE94ME5IUDZXZmlsR2hNaTZ0eTlwQ3RnTEZON0ZTV040OVRTM0Vtb3g3US1nTkZwQ0gtbGl1c0tmdE81U1pCS2tkZi03enNQSlpJUUtnRnRuVDBmUFpiUmI2V1Ffd1pFVFJNRWtfMWF2RDhNNUd5S0pQakcyM2hfclJmNG5ueW9FUjc2TGxCS2hfQThnMmdLM3BvWWlDVFlIX2dqVnJ6OC1IUllwOFBLejdTeGdEbjNXcktENV8xdGxlSUY?oc=5","date":"2026-01-29","type":"earnings","source":"Barchart.com","summary":"Fibromyalgia Market: Expanding Revenue Landscape to 2034 – DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma, UCB Biopharma SRL, GSK, UCB Pharma - Barchar","headline":"Fibromyalgia Market: Expanding Revenue Landscape to 2034 – DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Apti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxQQngzNlNpakZkTUV3Vmk4cTVkdnpZV2tGVExmLW9MM0oxa0QxaXNVcEx3SlNjTVJMUDdyWWxnU0ZkUXJndFhERm5HT0YzaVB1M2J0a3IyMWRpUDd4R1BQdVBEQTdSby1mZ2R0Uk5yblJDaGRGenpDVnAzdzJ2MEd0X0RYTGhDV3l3enJORGdFSUpRT3VzOENSdTcwQW9kZUNHc1cyMEpISUZHLWRURXZLVG9kRFAxem92bUdGTUR4Qmg2aXZmcy1WVmdKanFteGNDaHJYT0lfSjhIb1kyMnJDdVl1VEMwNldQUzRkNEdGaHljUDFfRXdub283V25uRHUyeXhacThROXFpRjFUcndwNnRXYmJZUE5fRU85S2hrMmRQZXJUMlJOc3hNV0VPNm9QX0JIeElCQkdUem9FYWo4b1REeDAxX3NQd2tvY1N3?oc=5","date":"2026-01-12","type":"deal","source":"PR Newswire","summary":"PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION - PR Newswire","headline":"PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-03","type":"deal","source":"PR Newswire","summary":"Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymp","headline":"Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) fo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgNBVV95cUxNWUpVd2tDVVRKYXNiandDQm1QTlk5ZW9wS1UwWHpWZWtUcE1hTGYzS0FqT0RhNURPRS1EN2JQbkt2LXBmdUZocE9MZXgzWmhWRHNLQnhnVW9IN1ZVLXB6NGMzRk9sajFWdXBqTTJKNm5WcS1ob1JUczdVbUU2V2ZfSzNpb2RIVGxOLUdGLUJ5MW9HLWtzd2NXLUxvc2QyWEZTX2t2aFZvZnlmMlRsNnZzdnF3RnpFZWo3VnZBU2pYaHFzeTdjcFVVMEN2a0hLXzNTcHdpR0lQQkd3eUU2UjlEOU8zU0duVF9uZjNqejVzMWYwajlrdWN1bTRkZ3RsRnYtUTRIdDFCUldaa1dqT08xd0VmbGdvRWhteDVGZGFNR0FfTWhsaW52LVRfcXhKZkx0amMtQjRWTkNaQjh0ZHZCNUgyYzNyYi1xb0lDRkUyWTl5NVA0aW9zNGJpUksyQ1Jsanp2RXBXZS1oaVZMRmZwcjRWbFhaRE1KV3dOZ0w5U3EwcEFiVGdxSHNQZExzb0h6cndlWTBn?oc=5","date":"2025-07-24","type":"regulatory","source":"PR Newswire","summary":"Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transp","headline":"Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxPSTRCTVl2bTlaOTJpc0MwQjVFODZxU2YtbmE2VXpQNHNtTDNfc1Qxa1lvZm5NTHNnYnFRcTg3ZVgwdWNGbVI3NVlYanhRRXJwOWZZTjFCTF9PclNuS3VYdU1zZzMzOHRhRTBoM0RFaWdOdHhHSXdRbnJKNGY3ZjVVdVlBUXJ5NThDd1dsR25YMExQZmFaYkozUnlBRVhoVFdwOXRJd0xYZjVFb2JSdE9kN1g2RmhaSms0Vzg1c0FQdTNRU21fYktNanhOZWxOdU9PQWdaMkdNZEZ3amxmMUlFc0VwNUVFRWtjMnh4Z3Y2NjVMVGlnaWVLbjQ4a29sM2V5SFVZemYya0V6SkhJaU91U1FxNURRSzJTbjhCWGQ1YUl4dw?oc=5","date":"2025-07-15","type":"pipeline","source":"PR Newswire","summary":"Pierre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. - PR Newswire","headline":"Pierre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Ata","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPZjVsVGliSlpoVWc5OV9WZDRQenpOVklvYmRVWjh5SWN1djVOVDFMVmQ2T1VTelh0N25kMVJaeUVtT0IzY3d4MDd5SEpod1dVZ0xUR2RuVDRyOUFPSjNSWnZEUjJSRWFHMXV1LTRwQ0drN1QtcU1IaGgzYnlJV2MwTmdreU13ak4xZG5hX1dnY0pJUmlCRVlieUZkRFhHeEV4WlhxWXIwS2xGc3J6cm9UcXVXWTF3eXBPTVNCVVJEaGNNaENsUUUzUFZZSklMTjQzZ3dYQ1B0blU3cFFnckhRTHF0MkZxN2wy?oc=5","date":"2023-06-02","type":"deal","source":"BioSpace","summary":"Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones - BioSpace","headline":"Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development m","sentiment":"neutral"}],"patents":[],"drugCount":19,"phaseCounts":{"marketed":5,"phase_2":4,"phase_3":9,"phase_1":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}